怡开和注射用丹参注射液治疗糖尿病微血管病变25例临床疗效分析被引量：1

下载PDF

导出

摘要目的怡开和丹参注射液都具有改善微循环障碍、扩张血管等作用,观察注射用丹参注射液配合口服怡开治疗糖尿病微血管病变(以糖尿病性耳鸣为例)的临床疗效。结论丹参注射液配合口服怡开治疗糖尿病微血管病变确实疗效显著。

作者肖伟

机构地区芜湖市第五人民医院老年病科(进修)

出处《中国医药指南》 2012年第3期232-233,共2页 Guide of China Medicine

关键词丹参注射液怡开糖尿病微血管病变治疗结果

分类号 R587.2 [医药卫生—内分泌] R28 [医药卫生—中药学]

引文网络
相关文献

参考文献4

1罗成仁.关于我国制订的糖尿病视网膜病变的分期标准[J].中华眼底病杂志,1998,14(3):131-131. 被引量：50
2王慧,娄晋宁.糖尿病微血管病变机制的研究进展[J].医学研究杂志,2010,39(8):101-104. 被引量：41
3张圭,薛耀明.糖尿病耳鸣是何故？[J].糖尿病之友,2009(8):30-30. 被引量：1
4杜云峰,成金罗.怡开在糖尿病慢性并发症防治中的作用[J].临床药物治疗杂志,2007,5(4):36-37. 被引量：3

二级参考文献25

1Ejaz S,Chekarova I,Ejaz A,et al.Importance of pericytes and mechanisms of pericyte loss during diabetes retinopathy.Diabetes Obes Metab,2008,10(1):53-63.
2Wolf G,Chen S,Ziyadeh FN.From the periphery of the glomerular capillary wall toward the center of disease:podocyte injury comes of age in diabetic nephropathy.Diabetes,2005,54(6):1626-1634.
3Yan SF,Ramasamy R,Schmidt AM.Mechanisms of disease:advanced glycation end-products and their receptor in inflammation and diabetes complications.Nat Clin Pract Endocrinol Metab,2008,4(5):285-293.
4Yamamoto Y,Kato I,Doi T,et al.Development and prevention of advanced diabetic nephropathy in RAGE overexpressing mice.J Clin Invest,2001,108(2):261-268.
5Thallas-Bonke V,Thorpe SR,Coughlan MT,et al.Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway.Diabetes,2008,57(2):460-469.
6Tuttle KR,Anderberg RJ,Cooney SK,et al.Oxidative Stress Mediates Protein Kinase C Activation and Advanced Glycation End Product Formation in a Mesangial Cell Model of Diabetes and High Protein Diet.Am J Nephrol,2008,29(3):171-180.
7Yokota T,Ma RC,Park JY,et al.Role of protein kinase C on the expression of platelet-derived growth factor and endothelin-1 in the retina of diabetic rats and cultured retinal capillary pericytes.Diabetes,2003,52(3):829-837.
8Idris I,Gray S,Donnelly R.Protein Kinase C activation:isozyme-specific effects on metabolism and cardiovascular complications in diabetes.Diabetologia,2001,44(6):659-673.
9Tuttle KR,Bakris GL,Toto RD,et al.The effect of ruboxistaurin on nephropathy in type 2 diabetes.Diabetes Care,2005,28(11):2686-2690.
10Shah DI,Singh M.Activation of protein kinase A improves vascular endothelial dysfunction.Endothelium,2006,13(4):267-277.